Psoriasis treatment gets personal: study aims to end Trial-and-Error
NCT ID NCT05270733
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks for gene markers that could predict how well a person with psoriasis will respond to certain FDA-approved drugs. About 56 participants will try two different psoriasis medications for 8 weeks each, while researchers take blood and skin samples. The goal is to make treatment more personalized and reduce the guesswork in finding the right drug.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Hospitals Cleveland Medical Center
RECRUITINGCleveland, Ohio, 44106, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new gel calm psoriasis Flare-Ups?
- Can a Once-Daily cream tame psoriasis in toddlers?
- Can a switch to guselkumab clear stubborn psoriasis?
- Can a new biologic clear stubborn psoriasis?
- Diet and exercise may tame psoriasis in kids — a trial puts it to the test
- Ancient herbal mix put to the test against psoriasis